DNLI News and Press, Denali Therapeutics Inc. From 02/15/19

Dosing is underway in a Phase 1b clinical trial evaluating Denali Therapeutics' (NASDAQ: DNLI ) DNL747 in Alzheimer's disease patients. The primary objectives are safety and biomarker data which will inform future studies. More news on: Denali Therapeutics, Inc., Sanofi, Healthcare st...

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of...

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...

Eiger BioPharmaceuticals (NASDAQ: EIGR ) initiated with Outperform rating and $47 (244% upside) price target at Baird. Shares up  13%  premarket. More news on: Eiger BioPharmaceuticals, Inc., Vericel Corporation, Denali Therapeutics, Inc., Healthcare stocks news, Stocks on the mo...

by Jonathan Liss Coming from a family of medical doctors, I am no stranger to sometimes pedantic conversations about the potential efficacy of a particular drug or therapeutic treatment. Not particularly adept as an investor, my father never seriously entertained the idea of using any...